Nathan Singh
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Nathan Singh is an Assistant Professor at Washington University School of Medicine in the United States. His research focuses on T-cell therapies, including TCR-based cell therapy, genome-edited T-cell therapies, and CAR T-cell therapy. Recent articles authored by Dr. Singh examine regulatory considerations, mechanisms of response to therapy, and advancements in the manipulation of the cancer-immunity cycle.
Articles (22)
Year:
2026
Methods to engineer the genomes of human cells for therapeutic intervention continue to advance at a remarkable pace. Chimeric antigen receptor–engineered T lymphocytes have pioneered the way for these therapies, initially beginning with insertions of chimeric antigen receptor transgenes into T-cell genomes using classical gene therapy vectors. The broad use of clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies to edit endogenous genes has now opened the door to a new era of precision medicine. To add complexity, many engineered cellular therapies under development integrate gene therapy with genome editing to introduce novel biological functions and enhance therapeutic efficacy. Here, we review the current state of scientific, translational, and regulatory oversight of gene-edited cell products.
Year:
2024
Year:
2024
Year:
2024
Supplementary Figure 3 | a, Predicted structures of miTCR1 and miTCR2 α and β chains overlaid on resolved structures of TCR α and β chains. b, Overlay of five highest-ranking predictions for miTCR1 and miTCR2 variable-constant chain interface. c, Resolved native TCR α chain V-C interface structure and predicted V-C interface structures of miTCR2 WT and modified α chains. d, Resolved native TCR β chain V-C interface structure and predicted V-C interface structures of miTCR1 WT, miTCR2 WT and modified β chains.
Year:
2024
Supplementary Figure 8 | a, Cytotoxicity, as measured by fold change in Nalm6 growth during co-culture, and b, expansion of human T cells expressing transgenic TCR 1G4, 19/BBζ or 19/28ζ CAR against Nalm6WT or Nalm6triple. c-d, Endogenous expression of 41BBL, CD80 and CD86 in c, Raji and d, K562 cell lines. e, Growth rate of engineered Nalm6 cell lines. f-g, Cytotoxicity of 19/BBζ CAR and mut035 T cells over time during f, acute stimulation and g, re-stimulation. 19/BBζ CAR were initially co-cultured with Nalm6WT and re-stimulated with Nalm6WT; mut035 T cells were initially co-cultured with Nalm641BBL and re-stimulated with Nalm6WT. h, Percent of cells expressing either 19/BBζ CAR or mut035 miTCR on day 0 or after five days of chronic stimulation with various Nalm6 cell lines. i, Expansion of 19/BBζ CAR or mut035 miTCR T cells over the course of chronic stimulation with various Nalm6 cell lines. a-b and f-g Representative data from three independent donors; i, Representative of five independent donors. Statistical significance determined using two-way ANOVA.
Year:
2024
Supplementary Figure 7 | a, Overlay of predicted mut031 α chain variable region and resolved FMC63 variable chain structure. Modeling performed using AlphaFold2. b, Memory lineages of human T cells engineered to express miTCR1 WT or mut035 at the conclusion of manufacturing cultures. c-d, Proportion of human T cells that were early lineage (naïve or central memory) c, throughout 6 day stimulation manufacturing cultures or d, one day after clearance of Nalm6. e, Expansion of human T cells expressing miTCR1 WT, mut035 or 19/BBζ CAR from two donors. b-d, data from one donor.
Year:
2024
Supplementary Figure 6 | a-b, Cytotoxicity of a, miTCR1 and b, miTCR2 variants against Nalm6. c-d, Long-term flow cytometry-based cytotoxicity of lead c, miTCR1 and d, miTCR2 variants. e, Quantification of cytokines in supernatants 24h after co-culture of engineered T cells with Nalm6. f, Expression of TCRC chains in αCD22 miTCR1, CD22 miTCR2 and CD19 miTCR1 engineered Jurkat cells. g, Induction of reporter NFAT-GFP upon exposure to CD19+CD22+ Nalm6 in Jurkat cells. Screening studies in a-b performed using two independent donors; c-d, representative data from three independent donors; e, data from one donor. ****P
Year:
2024
Supplementary Figure 5 | a-b, Expression of TCR constant chains on the surface of a, Jurkat and b, human T cells transduced with miTCR variants. c-d, Comparison of surface TCR expression in miTCR1 and miTCR2 variant engineered c, Jurkats and d, human T cells. e, Change in surface expression of TCR constant chains based on presence or absence of PD insertion in the miTCRα chain. f, Expression of NFAT and g, NFκB in reporter Jurkat cells expressing 1G4 or miTCR variants in response to Nalm6. h, Expansion of human T cells expressing miTCR1 and miTCR2 variants upon exposure to Nalm6. d, cumulative data from three independent donors. b,e, representative data from three independent donors. Screening studies in h performed using two independent donors. *P
Year:
2024
Supplementary Figure 2 | a-d, Expression of a, TCR constant chains and mCherry transduction marker, b, FMC63 and mCherry transduction marker, c, FMC63 and TCR constant chains and d, CD3ε and TCR constant chains in primary human T cells engineered with CARs or miTCRs. e, Comparison of surface FMC63 expression in miTCR1 and miTCR2 engineered T cells in n=6 independent donors. f, Median fluorescence intensity (MFI) of APC on T cells that bound soluble CD19-APC conjugate. a-d, Representative of five independent donors. Analysis using Student’s t-test or two-way ANOVA.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2021
Collaborators (7)
Saar I. Gill
University of Pennsylvania
Carl H. June
Professor
University of Pennsylvania
Joseph A. Fraietta
University of Pennsylvania
Gerald Linette
Professor
University of Pennsylvania
Alex Holehouse
Associate Professor
Washington University in Saint Louis School of Medicine
John F. DiPersio
Director, Center for Gene and Cellular Immunotherapy
Washington University in St. Louis
Michael Slade
Assistant Professor
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.